ABOUT US
NEWS
INVESTOR RELATIONS
简
繁
EN
ABOUT US
NEWS
INVESTOR RELATIONS
简
繁
EN
简
繁
EN
COMPANY NEWS
Essex Bio-Technology (1061.HK) 2024 Interim Results at a glance
2024.08.26
Essex Bio-Technology Reports 1st H 2024 Net Profit of HK$157.4 Million Poised for Future Success Underpinned by Proven Product Base and Promising Pipeline of Products
2024.08.26
Essex Bio-Technology Included in Forbes Asia's Best Under A Billion 2024
2024.08.26
Time
Last 7 days
Last 30 days
The last six months
Date
Title
2023-02-23
2023-02-22
Essex and Henlius signed amendment agreement for Global Co-Development and Exclusive License Agreement for treatment of age-related macular degeneration
2023-02-10
First Patient in the US Dosed in a Global Multicentre Phase 3 Clinical Study of Bevacizumab for treatment of Ophthalmic Diseases
2022-10-13
Essex Biotechnology Secures Exclusive Global Rights and Interests of SkQ1 in the field Ophthalmology from Mitotech
2022-08-24
Essex Bio-Technology (1061.HK) 2022 Interim Results at a Glance
2022-08-23
Essex Bio-Technology Announces 2022 Interim Financial Results
2022-08-15
Essex Bio-Technology Included in "Forbes Asia's Best Under A Billion 2022”
2022-07-15
EssexBio awarded “2021 China Pharmaceutical Industry Top 100 Series List” and “2022 China Pharmaceutical Brands List”
<
1
2
3
4
5
6
7
...
9
>